Thomas Rossi, MD
Sports Medicine · Dublin, OHNPI 1821083528
Payments from drug & device makers
Across 266 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$956
- Collegium Pharmaceutical, Inc.$344
- Biohaven Pharmaceutical Holding Company Ltd.$284
- Almatica Pharma LLC$268
- Ipsen Biopharmaceuticals, Inc$156
- plus $969 from 20 others
What the payments were for
- Food & beverage$4,293100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $1,316 |
| Pfizer | 70 | $956 |
| Collegium Pharmaceutical, Inc. | 25 | $344 |
| Biohaven Pharmaceutical Holding Company Ltd. | 25 | $284 |
| Almatica Pharma LLC | 18 | $268 |
| Ipsen Biopharmaceuticals, Inc | 8 | $156 |
| Biohaven Pharmaceuticals, Inc. | 11 | $116 |
| Amgen | 5 | $104 |
| Vertex | 4 | $104 |
| Arbor Pharmaceuticals, Inc. | 5 | $103 |
| Avanir Pharmaceuticals, Inc. | 6 | $99 |
| Abbott | 4 | $80 |
| Alfasigma USA, Inc. | 3 | $51 |
| Bioventus LLC | 3 | $47 |
| Merz Pharmaceuticals, LLC | 2 | $36 |
| Novartis | 2 | $35 |
| Lilly USA, LLC | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Saluda Medical Americas, Inc. | 1 | $30 |
| Endo USA, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $14 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$4,293 in reported general payments places this provider in the 65th percentile of 278 sports medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 169 | $7,500 |
| Pregabalin | 62 | $2,218 |
| Celecoxib | 48 | $2,190 |
| Duloxetine Hcl | 80 | $1,692 |
| Trazodone Hcl | 23 | $208 |
| Etodolac | 14 | $197 |
| Meloxicam | 29 | $87 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Dublin
- Thomas EllisDublin$427K
- Robert MagnussenDublin$193K
- Brian SkuraDublin$15K
- David FlaniganColumbus$1.7M
- Robert HeidtCincinnati$911K
- Paul SaluanCleveland$367K
- Vincent SammarcoCincinnati$361K
- Jovan LaskovskiAkron$337K
- Julie BishopColumbus$322K
- Brian GraweCincinnati$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.